Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

PD-L1 inhibitors

National Institute for Health and Care Excellence NICE logo

NICE questions cost of medicines development

Says pharma should determine if R&D spending of £1bn+ per drug is really necessary

- PMLiVE

Boehringer readies first cancer drug Gilotrif for US launch

Will mark milestone for the pharma company's oncology research efforts

National Institute for Health and Care Excellence NICE logo

NICE recommends tests to detect lung cancer mutation

Offers guidance on what NHS can use to see what patients have the EGFR gene mutation

Bristol-Myers Squibb (BMS) building

BMS drops antidepressant in phase IIb

Liafensine no better than Lilly’s Cymbalta

- PMLiVE

Avanir to co-promote Merck’s diabetes drugs in the US

Will market Januvia and Janumet to care homes

- PMLiVE

Roche loses Herceptin patents in India

Government says pharma company did not follow correct filing procedure

- PMLiVE

GSK loses patent on Tykerb in India

Cuts period of exclusivity by two years

- PMLiVE

UK court upholds Teva’s patent on Copaxone

Dismisses challenge from Mylan

- PMLiVE

AZ and BMS try again with Forxiga in the US

Pharma companies re-submit diabetes drug to the FDA for approval

- PMLiVE

UCB files Vimpat patent claims against 15 companies

Aurobindo, Glenmark, Mylan, Ranbaxy and Sandoz all face legal challenge over generic versions of UCB's epilepsy drug

- PMLiVE

Setback for Teva as court dismisses Copaxone lawsuit

District Court dismisses claim that Mylan breached Teva’s patents on MS drug

- PMLiVE

Merck maintains lead in BACE inhibitors for Alzheimer’s

Positive results in phase Ib study in patients with Alzheimer’s disease

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links